ArticleScientific reports2024

HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.

Ansh Kapil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.